Icure Pharmaceutical In KRX:175250KOSDAQ
아이큐어 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days3
Articles tracked0since Sep 11
In Q2 2026, Icure Pharmaceutical In reported revenue of ₩37.7bn, up 49.1% year on year, and operating profit of ₩2.4bn. Icure Pharmaceutical In (아이큐어) appeared in 0 Korean news articles and 3 DART filings over the past seven days.
Icure Pharmaceutical In quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩37.7bn | +49.1% | ₩2.4bn | ₩2.3bn |
| Q1 2026 | ₩32.2bn | +45.5% | ₩208m | −₩669m |
| Q4 2025 derived | ₩10.9bn | -47.5% | −₩1.8bn | −₩18.4bn |
| Q3 2025 | ₩25.1bn | +59.8% | −₩3.3bn | −₩3.9bn |
| Q2 2025 | ₩25.3bn | +50.0% | −₩4.4bn | −₩9.8bn |
| Q1 2025 | ₩22.1bn | +38.9% | −₩2.4bn | −₩2.5bn |
| Q4 2024 derived | ₩20.7bn | +71.0% | −₩4.6bn | −₩16.2bn |
| Q3 2024 | ₩15.7bn | +5.1% | −₩4.4bn | ₩21.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Icure Pharmaceutical In top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Icure Pharmaceutical In news Korean headlines
No articles yet.